ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconFacebook IconIcon FacebookGoogle Plus IconLayer 1InstagramCreated with Sketch.Linkedin IconIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerIcon Opinion QuotePositive ArrowIcon PrintRSS IconIcon SearchSite TitleTitle ChevronTwitter IconIcon TwitterYoutube Icon

Welcome to our new website

As well as being able to load content faster than ever before, you'll now find it's much easier to find all the content you need about the Asian business world.

Science

Fujifilm to partner with Takeda on regenerative heart medicine

Clinical trials scheduled for drug that uses induced pluripotent stem cells

NIKKEI Staff writers

TOKYO -- Fujifilm will partner with Takeda Pharmaceutical to develop and sell a regenerative medicine product for heart patients, the company announced Thursday.

The deal combines Fujifilm's manufacturing expertise with Takeda's experience in clinical tests and pharmaceutical sales. The product, which is being developed by Fujifilm's U.S. subsidiary Cellular Dynamics International, uses induced pluripotent stem cells.

The companies expect the product, which helps restore the heart muscle in patients with grave heart failure symptoms, to begin clinical tests as early as 2019. It is currently being tested on lab animals.

The deal represents the first tie-up for the two companies.

Fujifilm acquired Wako Pure Chemical Industries, a laboratory chemicals manufacturer, from Takeda in 2017.

See Also

Read Next

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

{{sentenceStarter}} {{numberReadArticles}} free article{{numberReadArticles-plural}} this month

Stay ahead with our exclusives on Asia; the most dynamic market in the world.

Benefit from in-depth journalism from trusted experts within Asia itself.

Try 3 months for $9

Offer ends September 30th

Your trial period has expired

You need a subscription to...

See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

See all offers
NAR on print phone, device, and tablet media